Objective determination of PD-L1 protein levels in NSCLC reveals heterogeneity within tumors and prominent interassay variability or discordance. This could be due to different antibody affinities, limited specificity, or distinct target epitopes. Efforts to determine the clinical value of these observations are under way.
No takes yet. Share an insight, caveat, or question.
McLaughlin et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: